Bluesail Medical has completed the transfer of its 100% equity stake in Wuhan Bikail Rescue Products Co., Ltd. to Mingde Biotech. Mingde Biotech has paid the full equity transfer price of 190 million yuan, Wuhan Bikail has completed the industrial and commercial registration change procedures, and Bluesail Medical no longer holds any equity in it. In light of the equity structure and management framework adjustments brought about by this equity transfer, Zhang Yongchen has applied to resign from his position as vice president of the company, and after resigning will serve full-time in a management role at Wuhan Bikail. In the first quarter of 2026, Bluesail Medical achieved revenue of 1.625 billion yuan and net profit attributable to the parent company of 960,000 yuan.
Blue Sail Medical Co LtdCompleted sale of Bikail stake for 190 million yuan, but impact on overall company unclear.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class ACompany sold to Mingde Biotech; full payment received, but future impact not detailed.
